Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Wednesday. The firm issued a hold rating on the stock.

EKSO has been the subject of a number of other research reports. Lake Street Capital assumed coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They set a buy rating and a $2.50 price objective for the company. HC Wainwright restated a buy rating and issued a $10.00 price objective on shares of Ekso Bionics in a research report on Tuesday, July 30th.

Ekso Bionics Stock Performance

Shares of EKSO stock opened at $1.04 on Wednesday. The stock’s 50-day moving average is $1.10 and its two-hundred day moving average is $1.19. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. Ekso Bionics has a 1 year low of $0.68 and a 1 year high of $3.13. The firm has a market cap of $18.90 million, a price-to-earnings ratio of -1.07 and a beta of 1.45.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, July 29th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The firm had revenue of $4.95 million for the quarter, compared to analyst estimates of $5.34 million. During the same period last year, the firm earned ($0.31) EPS. Analysts predict that Ekso Bionics will post -0.42 earnings per share for the current year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC increased its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. 6.42% of the stock is owned by institutional investors and hedge funds.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.